GlassScriptPhysician profile
Nisreen A Haideri
NPI 1487682092
$1,527.86
in general payments reported to CMS, 2019-2025
23 companies · $596 in 2025
The $596 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $13.93 · 2022: $13.76 · 2023: $226 · 2024: $678 · 2025: $596.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,480 · Education: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,480.17 |
| Education | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $427.30 | 2023-2025 | |
| Abbvie INC. | $178.09 | 2023-2025 | |
| Array Biopharma INC | $159.05 | 2023-2024 | Braftovi, Mektovi, Lorbrena |
| Genentech USA, INC. | $146.65 | 2024-2025 | Tecentriq, Itovebi, Polivy |
| Glaxosmithkline, LLC. | $124.98 | 2024-2025 | Zejula, Jemperli, Ojjaara |
| Celgene Corporation | $91.49 | 2024-2025 | Reblozyl, Pomalyst, Opdualag |
| Aveo Pharmaceuticals, INC. | $74.87 | 2025 | |
| Foundation Medicine, INC. | $66.23 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $41.49 | 2023-2024 | Opdivo, Opdualag |
| Astrazeneca Pharmaceuticals LP | $38.78 | 2024 | Lynparza |
| Merck Sharp & Dohme LLC | $36.96 | 2024-2025 | Keytruda, Welireg |
| Daiichi Sankyo INC. | $28.97 | 2024 | Enhertu |
| Eisai INC. | $28.42 | 2022-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.97 | 2025 | |
| Novartis Pharmaceuticals Corporation | $20.88 | 2024 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $14.67 | 2024 | Cabometyx |
| Janssen Biotech, INC. | $14.13 | 2025 | Carvykti |
| Acrotech Biopharma INC. | $13.93 | 2021 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nisreen Haideri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.